News | October 22, 2008

Sweden Implants First CardioWest Bridge-to-Transplant Artificial Heart

October 23, 2008 - SynCardia announced that on Oct. 15, Dr. Lars Wiklund, chief of cardiothoracic surgery at Sahlgrenska University Hospital in Gothenburg, Sweden, led a surgical team in implanting the CardioWest temporary total artificial heart into a 31-year-old male patient, making it the first Swedish implant of the device.

Dr. Ulf Kjellman, head of the hospital’s ventricular assist device (VAD) program, performed the implant.

“If it weren’t for the CardioWest artificial heart, this patient would have died,” said Dr. Kjellman. “Both sides of his heart were failing. He needed a heart transplant to survive, but no donor heart was available. His only option was for us to implant the CardioWest artificial heart as a bridge-to-transplant. The artificial heart will make him a stronger and healthier transplant candidate while he waits for a matching donor heart.”

In some countries in Europe, artificial heart patients can wait up to two years for a matching donor heart. Since July 16, 2006, stable CardioWest patients in Europe have been able to recover at home thanks to the CE-approved portable driver.

During Q4 2008, SynCardia will apply to the FDA to conduct an IDE clinical study of the Companion Driver System in the U.S. and will also apply for CE approval in Europe. The Companion Driver is designed for use in both the hospital and at home. SynCardia projects a 400 percent increase in the number of patients benefiting from the CardioWest artificial heart in the 24 months following regulatory approvals.

Sweden joins Germany, France, Austria and Italy as the fifth European country with a hospital certified to implant the CardioWest artificial heart.

For more information: www.syncardia.com

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init